A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

NCT06323161 · Completed

Last updated 2026-05-28

This study is testing how the medication CagriSema affects blood sugar and body weight in adults with type 2 diabetes who are already taking a once-daily long-acting insulin, with or without metformin.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 274 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-03 · est. completion 2025-10

Where 53 sites · China, Japan, Serbia, Slovakia, South Africa, United States

What this study is testing ClinicalTrials.gov NCT06323161 ↗

Description as written by the study sponsor.

This study will look at how much CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a "dummy" medicine (also called "placebo") that has no effect on the body. Participant will get either CagriSema or "dummy" medicine and which treatment they get is decided by chance. Participant will take the study medicine together with their current diabetes medicine (once-daily insulin with or without metformin). For each participant, the study will last for about one year.

Treatments tested

Cagrilintide Drug

Participants will receive once-weekly cagrilintide subcutaneously.
Semaglutide Drug

Participants will receive once-weekly semaglutide subcutaneously.
Placebo Drug

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Main thing measured	Change in Glycated Haemoglobin (HbA1c)
Sponsor	Novo Nordisk A/S
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06323161 ↗